Deutsche Bank AG purchased a new stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 114,487 shares of the company's stock, valued at approximately $2,135,000. Deutsche Bank AG owned 0.08% of Trevi Therapeutics as of its most recent SEC filing.
Several other large investors have also made changes to their positions in the business. Russell Investments Group Ltd. grew its position in shares of Trevi Therapeutics by 194.5% during the second quarter. Russell Investments Group Ltd. now owns 4,536 shares of the company's stock worth $25,000 after purchasing an additional 2,996 shares in the last quarter. KBC Group NV bought a new position in Trevi Therapeutics in the 1st quarter worth approximately $29,000. Hilton Head Capital Partners LLC purchased a new stake in Trevi Therapeutics during the 4th quarter valued at approximately $40,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Trevi Therapeutics during the fourth quarter valued at approximately $50,000. Finally, Strs Ohio bought a new stake in shares of Trevi Therapeutics during the first quarter valued at approximately $52,000. 95.76% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
TRVI has been the subject of a number of research reports. B. Riley Financial upped their target price on shares of Trevi Therapeutics from $21.00 to $31.00 and gave the stock a "buy" rating in a research report on Monday, July 20th. JonesTrading lifted their price target on shares of Trevi Therapeutics from $24.00 to $28.00 and gave the company a "buy" rating in a report on Friday, August 14th. Morgan Stanley reiterated an "overweight" rating and issued a $23.00 price target on shares of Trevi Therapeutics in a research note on Friday, August 7th. Oppenheimer increased their price objective on shares of Trevi Therapeutics from $24.00 to $25.00 and gave the company an "outperform" rating in a report on Friday, August 7th. Finally, BMO Capital Markets assumed coverage on Trevi Therapeutics in a research report on Monday, July 20th. They set an "outperform" rating and a $36.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $27.08.
Read Our Latest Report on TRVI
Trevi Therapeutics Stock Performance
Trevi Therapeutics stock opened at $17.96 on Friday. The company has a market capitalization of $2.56 billion, a PE ratio of -52.82 and a beta of 1.03. The company has a 50 day moving average price of $18.05 and a 200-day moving average price of $14.76. Trevi Therapeutics, Inc. has a fifty-two week low of $6.93 and a fifty-two week high of $20.22.
Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.11). On average, analysts forecast that Trevi Therapeutics, Inc. will post -0.48 earnings per share for the current year.
About Trevi Therapeutics
(
Free Report)
Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.
Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Trevi Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Trevi Therapeutics wasn't on the list.
While Trevi Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
